Ramsay Health Care Limited (ASX: RHC)- Ramsay Health Care arrowed down on ASX as net profit declined 20.6%

Ramsay Health Care (ASX: RHC) reported 7.0% rise in core earnings per share to 279.8 cents and 6.8% rise in core net profit to $579.3 million for the year ended 30 June 2018. Group’s revenue increased 5.4% to $9.2 billion including 5.5% growth in Australia/Asia segment, 0.3% growth in France, and decline of 5.2% in United Kingdom arising from significant downturn in NHS volumes.

Group’s earnings before interest tax, depreciation and amortization (EBITDA) rose to $1.4 billion, an increase of 6.2% on FY17. However, statutory reported net profit after tax of the company declined by 20.6% to $388.3 million, reflecting net non-core items of $191.0 million in FY18. [optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

Private Hospital operator Ramsay Health Care has completed projects with gross capital investment of $171 million in fiscal 2018, which includes net increase of four beds, seven theaters and 21 consulting suites.

Fully-franked final dividend of 86.5 cents was announced during the year, taking the full year 2018 dividend to 144.0 cents which is 7.1% more than previous year dividend payment.

After taking into consideration the anticipation of higher interest and tax in FY19, the company aims of up to 2% growth in Core EPS.

As company reported downfall in net profit after tax, Ramsay’s stock slipped by 7.221% to $53.960 on 30 August 2018 (3:32 PM AEST).

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report